Product Search

#27267 Human GPIHBP1 Autoantibody Assay Kit - IBL

  • #27267 Human GPIHBP1 Autoantibody ELISA Kit
  • #27267 Human GPIHBP1 Autoantibody ELISA Kit
  • #27267 Human GPIHBP1 Autoantibody ELISA Kit
Intended Use:
Research reagents
Measuring Method:
Sample Types:
Measuring Samples:
Serum, EDTA-plasma, Heparin plasma, Post-heparin EDTA-plasma
Measurement Range:
0.008 - 0.500 U/mL
Package Size1:
96 Well

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
  for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
  enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 27267
Product Name Human GPIHBP1 Autoantibody Assay Kit - IBL
Maker Name Immuno-Biological Laboratories Co., Ltd.
Intended Use Research reagents
Measuring Method ELISA
Conjugate HRP
Species Human
Measuring Samples Serum, EDTA-plasma, Heparin plasma, Post-heparin EDTA-plasma
Measurement Range 0.008 - 0.500 U/mL
Primary Reaction 60 minutes at 25 ℃
Secondary Reaction 30 minutes at 25 ℃
Sensitivity 0.001 U/mL
Storage Condition 2 - 8 ℃
Poisonous and Deleterious Substances Not Applicable
Cartagena Not Applicable
Measuring Service Not Available
Package Size 1 96 Well

Product Description

Product Description

GPIHBP1 (Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) is an anchor protein that is modified by glycolipid and it has been known that it exists on a capillary endothelial cell membrane and involves with metabolism of triglyceride rich (TG-rich) lipoprotein (triglyceride). 

GPIHBP1 transports lipoprotein lipase (LPL) synthesized and secreted in adipocyte or skeletal muscle cells into capillary lumen by transcytosis and it binds LPL on the surface of endothelial cells so that GPIHBP1 has an critical role for metabolizing TG-rich lipoprotein.

It has been already know that type I hyperlipemia (hyperchylomicronemia) can be caused by GPIHBP1 gene mutation, however, the new insight regarding existence of GPIHBPI autoantibody as a novel disease entity has been reported on the following paper published by New England Journal of Medicine (NEJM).

Beigneux AP, Miyashita K, Ploug M, et al. Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. N Engl J Med. 2017;376(17):1647-1658. doi:10.1056/NEJMoa1611930

According to the new insight, GPIHBP1 antibody against to GPIHBP1 protein interferes the binding between GPIHBP1 and LPL, then it blocks the transport of LPL by GPIHBP1. At the end, severe hyperchylomicronemia is caused by the phenomenon as same as gene mutation.

This kit can quantitatively measure GPIHBP1 autoantibody in human serum and EDTA-plasma samples.

References (Not listed at PubMed)
A Woman With HypertriglyceridemiaWho Acquired AntibodyAgainst GPIHBP1 Hirano et al. JACC:  CASE  REPORTS